Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · IEX Real-Time Price · USD
2.010
+0.010 (0.50%)
Apr 19, 2024, 3:12 PM EDT - Market open
Coherus BioSciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 102.89 | 63.55 | 417.2 | 541.16 | 177.67 | 72.41 | 126.97 | 125.01 | 158.29 | 150.45 | Upgrade
|
| Short-Term Investments | 14.86 | 128.13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.82 | Upgrade
|
| Cash & Cash Equivalents | 117.75 | 191.68 | 417.2 | 541.16 | 177.67 | 72.41 | 126.97 | 125.01 | 158.29 | 152.27 | Upgrade
|
| Cash Growth | -38.57% | -54.05% | -22.91% | 204.59% | 145.38% | -42.97% | 1.57% | -21.02% | 3.95% | 283.44% | Upgrade
|
| Receivables | 260.52 | 109.96 | 123.02 | 157.05 | 141.99 | 0 | 0 | 1.86 | 1.56 | 2.42 | Upgrade
|
| Inventory | 130.1 | 115.05 | 93.25 | 92.19 | 55.07 | 5.67 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Current Assets | -32.74 | -35.46 | -31.15 | -22.91 | -31.72 | 6.36 | 18.51 | 34.62 | 37.54 | 24.45 | Upgrade
|
| Total Current Assets | 475.63 | 381.23 | 602.32 | 767.48 | 343.01 | 84.43 | 145.48 | 161.49 | 197.39 | 179.14 | Upgrade
|
| Property, Plant & Equipment | 5.12 | 8.75 | 7.81 | 10.11 | 16.49 | 6.66 | 12.77 | 10.77 | 10.5 | 4.47 | Upgrade
|
| Long-Term Investments | 0 | 0 | 0 | 0 | 0.24 | 0.79 | 0.79 | 0.79 | 0.79 | 0 | Upgrade
|
| Goodwill and Intangibles | 71.67 | 5.93 | 3.56 | 3.56 | 3.56 | 3.56 | 3.56 | 3.56 | 3.56 | 3.56 | Upgrade
|
| Other Long-Term Assets | 77.18 | 84.93 | 65.64 | 60.5 | 45.63 | 4.03 | 0.01 | 1.88 | 0.15 | 0.05 | Upgrade
|
| Total Long-Term Assets | 153.97 | 99.61 | 77.01 | 74.17 | 65.92 | 15.03 | 17.13 | 17 | 15 | 8.09 | Upgrade
|
| Total Assets | 629.6 | 480.85 | 679.33 | 841.65 | 408.93 | 99.47 | 162.61 | 178.49 | 212.38 | 187.22 | Upgrade
|
| Accounts Payable | 35.22 | 11.53 | 16.16 | 15.2 | 25.99 | 15.29 | 15.71 | 20.58 | 29.5 | 10.8 | Upgrade
|
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.56 | 94.96 | 62.7 | Upgrade
|
| Other Current Liabilities | 296.55 | 127.17 | 149.17 | 130.45 | 88.98 | 17.97 | 12.68 | 34.23 | -18.44 | -21.71 | Upgrade
|
| Total Current Liabilities | 331.77 | 138.69 | 165.33 | 145.65 | 114.97 | 33.26 | 28.4 | 56.38 | 106.02 | 51.78 | Upgrade
|
| Long-Term Debt | 478.7 | 476.1 | 415.53 | 413.97 | 188.64 | 103.09 | 101.61 | 100.26 | 0 | 0 | Upgrade
|
| Other Long-Term Liabilities | 12.56 | 3.47 | 0.75 | 1.05 | 0.1 | 1.71 | 2.07 | 2.5 | 113.3 | 68.68 | Upgrade
|
| Total Long-Term Liabilities | 491.26 | 479.57 | 416.28 | 415.02 | 188.74 | 104.8 | 103.68 | 102.76 | 113.3 | 68.68 | Upgrade
|
| Total Liabilities | 823.03 | 618.27 | 581.61 | 560.68 | 303.71 | 138.06 | 132.08 | 159.13 | 219.31 | 120.46 | Upgrade
|
| Total Debt | 478.7 | 476.1 | 415.53 | 413.97 | 188.64 | 103.09 | 101.61 | 100.26 | 0 | 0 | Upgrade
|
| Debt Growth | 0.54% | 14.58% | 0.38% | 119.45% | 82.98% | 1.46% | 1.35% | - | - | - | Upgrade
|
| Retained Earnings | -1,579.5 | -1,341.61 | -1,049.85 | -762.75 | -895 | -984.83 | -775.49 | -537.32 | -409.99 | -186.73 | Upgrade
|
| Comprehensive Income | -0.25 | -0.25 | -0.27 | -0.27 | -0.56 | -0.28 | -0.75 | -0.63 | -0.4 | -0.53 | Upgrade
|
| Shareholders' Equity | -193.43 | -137.42 | 97.73 | 280.97 | 105.21 | -38.59 | 31.82 | 20.53 | -6.21 | 66.8 | Upgrade
|
| Net Cash / Debt | -360.95 | -284.42 | 1.66 | 127.19 | -10.97 | -30.69 | 25.36 | 24.75 | 158.29 | 152.27 | Upgrade
|
| Net Cash / Debt Growth | - | - | -98.69% | - | - | - | 2.47% | -84.36% | 3.95% | 328.82% | Upgrade
|
| Net Cash Per Share | -3.83 | -3.66 | 0.02 | 1.78 | -0.15 | -0.47 | 0.48 | 0.59 | 4.26 | 18.60 | Upgrade
|
| Working Capital | 143.86 | 242.54 | 437 | 621.83 | 228.04 | 51.17 | 117.08 | 105.11 | 91.37 | 127.35 | Upgrade
|
| Book Value Per Share | -2.05 | -1.77 | 1.29 | 3.94 | 1.51 | -0.59 | 0.60 | 0.49 | -0.17 | 8.16 | Upgrade
|